Management of Acquired Hypothalamic Obesity After Childhood-Onset Craniopharyngioma—A Narrative Review

Biomedicines, Год журнала: 2025, Номер 13(5), С. 1016 - 1016

Опубликована: Апрель 22, 2025

Introduction: Craniopharyngiomas are rare sellar embryonic malformational tumors of low-grade histological malignancy. Despite high overall survival rates (92%), quality life is frequently reduced due to adverse late effects caused by hypothalamic obesity. It well known that morbid obesity associated with the grade damage. Accordingly, craniopharyngioma should be considered a paradigmatic disease, reflecting challenges in diagnosis and treatment acquired Methods: A narrative review was performed after searching MEDLINE/PubMed, Embase, Web Science databases for initial identifying articles. The search terms childhood-onset were used. Results: availability promising therapeutic approaches, such as medication central stimulating agents, antidiabetic drugs, glucagon-like peptide 1 (GLP1) receptor agonists, Setmelanotide, it must emphasized there currently no pharmaceutical proven effective randomized controlled trials. For prospective blinded trial over 12-month period ongoing. Bariatric interventions effective, but non-reversible procedures bypass operations controversial pediatric age group legal ethical concerns. Recently, algorithm introduced improve management syndrome/obesity offering more personalized treatment. Decisions on strategies focusing preservation visual, neuroendocrine, integrity made experienced multidisciplinary teams. Conclusions: Treatment approaches limited. Further research novel warranted craniopharyngioma.

Язык: Английский

Hypothalamic-pituitary dysfunction in children with suprasellar tumors

Опубликована: Окт. 5, 2023

The main aim of this thesis is to obtain more insight in the risk factors and evaluate new treatments for hypothalamic-pituitary (HP) dysfunction children with a suprasellar brain tumor. Improving knowledge on presence consequences HP (suprasellar) tumor hopefully improves their outcome quality life may reduce health care costs long run. In part I (HP childhood craniopharyngioma), we focus identifying treatment cCP relation outcome. II (The clinical domains dysfunction), assessment dysfunction, diagnostics options signs symptoms within each separate domain (psychosocial disorders, hyperphagia, sleep disturbances, decreased energy expenditure, hyperinsulinemia/insulin resistance, pituitary dysfunction). last part, III other survivors), describe survivors tumors, excluding craniopharyngioma. Part Ι. craniopharyngioma chapter 2, discuss key aspects presentation cCP, including factors, current available therapeutic agents hypothalamic dysfunction. Chapter 3 presents nationwide retrospective review diagnosed period 2004 - 2021, evaluating effect shifting strategy ΙΙ. Signs assessed per 4, propose diagnostic criteria score syndrome. Moreover, evaluated score, two cohorts cohort low-grade glioma. 5, possibility deep stimulation (DBS) as option neurobehavioral patients obesity. 6 reports multicenter study dextroamphetamine 7, provide an overview etiology disturbances tumors. addition, flowchart help clinicians diagnose problems after (supra)sellar 8 tumors whom resting consumption was measured. We utility such measurements. 9 describes case series acquired obesity who were treated GLP-1 receptor agonist, improving BMI. 10 focuses safety GH replacement cCP. This includes systematic study. 11 prevalence associations growth elevated IGF-1 concentrations LGG children. III. 12 significant weight gain, overweight obesity, CBTS,

Язык: Английский